Bevacizumab and daily temozolomide for recurrent glioblastoma

Cancer

Volumn 118, Issue 5, 2012, Pages 1302-1312

  Desjardins, Annick ^a   Reardon, David A ^a   Coan, April ^a   Marcello, Jennifer ^a   Herndon II, James E ^a   Bailey, Leighann ^a   Peters, Katherine B ^a   Friedman, Henry S ^a   Vredenburgh, James J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiogenesis inhibitors; bevacizumab; glioblastoma; recurrent; temozolomide; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COLITIS; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; GLIOBLASTOMA; HEMATURIA; HEMORRHOID; HOARSENESS; HUMAN; HYPERPIGMENTATION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; RECURRENT CANCER; THROMBOCYTOPENIA; VOMITING; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857373272     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26381     Document Type: Article

References (54)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578. (Pubitemid 29368260)
2. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol. 2008; 10: 162-170.
3. Ballman KV, Buckner JC, Brown PD, et al. The relationship between 6-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncol. 2007; 9: 29-38. (Pubitemid 46543486)
4. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17: 1516-1525. (Pubitemid 29220860)
5. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003; 97 (9 suppl): 2381-2386. (Pubitemid 36444049)
6. Chamberlain MC,. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002; 56: 183-188. (Pubitemid 34272310)
7. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncol. 2006; 8: 189-193. (Pubitemid 46542664)
8. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588-593. (Pubitemid 30636298)
9. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004; 63: 1281-1284. (Pubitemid 39350031)
10. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004; 22: 4779-4786.
11. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncol. 2006; 8: 67-78. (Pubitemid 43154453)
12. Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009; 101: 1995-2004.
13. Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010; 96: 393-402.
14. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol. 2009; 27: 1268-1274.
15. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY,. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncol. 2010; 12: 603-607.
16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. (Pubitemid 40349501)
17. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. (Pubitemid 40349502)
18. Brandes AA, Franceschi E, Tosoni A, et al. O-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-Oncol. 2010; 12: 283-288.
19. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer. 2007; 121: 2458-2464. (Pubitemid 350022415)
20. Parkinson JF, Wheeler HR, Clarkson A, et al. Variation of O-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol. 2008; 87: 71-78.
21. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 1004-1011. (Pubitemid 36560766)
22. Kerbel RS, Kamen BA,. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4: 423-436. (Pubitemid 38745528)
23. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003; 63: 4342-4346. (Pubitemid 36951001)
24. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010; 28: 2051-2057.
25. Kleihues P,. On bilateral symmetrical infarct of the occipital lobe. Pathology and clinico-ophthalmological findings [in German]. Dtsch Z Nervenheilkd. 1966; 188: 25-52.
26. Reijneveld JC, Voest EE, Taphoorn MJ,. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol. 2000; 247: 597-608.
27. Chaudhry IH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS,. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 2001; 39: 409-415. (Pubitemid 32990094)
28. Ke LD, Shi YX, Im SA, Chen X, Yung WK,. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res. 2000; 6: 2562-2572. (Pubitemid 30399229)
29. Plate KH, Breier G, Weich HA, Risau W,. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359: 845-848.
30. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995; 55: 1189-1193.
31. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362: 841-844. (Pubitemid 23132159)
32. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57: 4593-4599. (Pubitemid 27441066)
33. Ferrara N,. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25: 581-611. (Pubitemid 39099316)
34. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
35. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729. (Pubitemid 350086473)
36. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280. (Pubitemid 20195640)
37. McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS,. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest. 1998; 78: 643-644. (Pubitemid 28246989)
38. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998; 16: 3851-3857. (Pubitemid 29001538)
39. Pope WB, Xia Q, Das A, et al. Patterns of progression in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study. Neuro-Oncol. 2009; 11: 563-699.
40. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009; 73: 1200-1206.
41. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779-787.
42. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010; 28: 1963-1972.
43. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003; 14: 603-614. (Pubitemid 41295091)
44. Wick W, Weller M,. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol. 2005; 23: 4235-4236; author reply 4236. (Pubitemid 46211332)
45. Neyns B, Chaskis C, Joosens E, et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest. 2008; 26: 269-277. (Pubitemid 351329006)
46. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2006; 95: 1155-1160. (Pubitemid 44658477)
47. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M,. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004; 62: 2113-2115. (Pubitemid 38738235)
48. Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M,. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol. 2012; 103: 585-593.
49. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25: 3357-3361. (Pubitemid 47325623)
50. Kong DS, Lee JI, Kim JH, et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro-Oncol. 2010; 12: 289-296.
51. Perry JR, Rizek P, Cashman R, Morrison M, Morrison T,. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008; 113: 2152-2157.
52. Maxwell JA, Johnson SP, Quinn JA, et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther. 2006; 5: 2531-2539. (Pubitemid 44650917)
53. Chamberlain MC,. Radiographic patterns of relapse in glioblastoma. J Neurooncol. 2011; 101: 319-323.
54. Verhoeff JJ, Lavini C, van Linde ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010; 21: 1723-1727.